Last $8.96 USD
Change Today -0.09 / -0.99%
Volume 115.0
NBHGY On Other Exchanges
SIX Swiss Ex
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

nobel biocare hold-unsp adr (NBHGY) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/29/14 - $9.99
52 Week Low
05/7/14 - $6.82
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

nobel biocare hold-unsp adr (NBHGY) Related Businessweek News

No Related Businessweek News Found

nobel biocare hold-unsp adr (NBHGY) Details

Nobel Biocare Holding AG operates in the field of implant-based dental restorations worldwide. It offers dental implants for various indications, bone types, and surgical protocols under the NobelActive, Brånemark System, and NobelReplace brands; high-precision individualized prosthetics and CAD/CAM systems for every indication, from a single tooth to edentulous jaws, on natural teeth and implants under the NobelProcera brand; and machined and TiUnite implants. The company also provides a range of individualized CAD/CAM abutments and a portfolio of prefabricated temporary and final abutments; biomaterials for soft tissue and bone regeneration under the creos brand; and removable and fixed implant-supported restorations. In addition, it offers NobelClinician software for enhanced diagnostics and treatment planning; and NobelGuide, a treatment concept for diagnostics, prosthetic-driven treatment planning biomaterials and guided implant surgery. Nobel Biocare Holding AG provides training and education, as well as a range of practice support and patient information materials to its customers. The company markets its products to dental healthcare professionals comprising oral surgeons, general practitioners, specialists, and laboratories. Nobel Biocare Holding AG was founded in 1981 and is headquartered in Kloten, Switzerland.

2,544 Employees
Last Reported Date: 08/21/14
Founded in 1981

nobel biocare hold-unsp adr (NBHGY) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.2.0M
Compensation as of Fiscal Year 2013.

nobel biocare hold-unsp adr (NBHGY) Key Developments

Danaher Corp., Nobel Biocare Holding AG - M&A Call

To enter into definitive transaction agreement with Nobel Biocare Holding AG

Nobel Biocare Holding AG Presents at Goldman Sachs 11th Annual European Medtech And Healthcare Services Conference, Sep-03-2014

Nobel Biocare Holding AG Presents at Goldman Sachs 11th Annual European Medtech And Healthcare Services Conference, Sep-03-2014 . Venue: London, United Kingdom.

Nobel Biocare Holding AG Reports Earnings Results for the Six Months of 2014; Revised Earnings Guidance for 2014

Nobel Biocare Holding AG reported earnings results for the six months of 2014. For the first six months, the company's revenue was EUR 283 million, up 2.5% from last year at constant exchange rates. In its reporting currency, sales were down 2.2% due to ongoing significant adverse currency impact. Speaking of currencies, the company experienced in the second quarter a continued adverse impact comparable to the one in the first quarter throughout the whole P&L. This also led to a less favorable net financial result than in the same period a year ago. The reduction of the operating expense led to a material expansion of the operating profit and the respective margin on a like-for-like basis. Operating profit was up 26% compared with last year and excluding the nonrecurring cost in 2013. EBIT margin was at 15%. Constant exchange rate, the margin would have been at 15.8%, up around 300 basis points from a year ago. Net profit was EUR 42 million, which was up 25% at constant exchange rates over last year, reflecting a net profit margin of now around 10%. Cash flow from operating activities was solid in the first half of the year, but around EUR 7 million below last year. The reason for this is higher cash outflows from accrued expenses for bonuses and taxes compared to a year ago. The company maintained its outlook of 3% to 4% revenue growth for the year. The company will need to accelerate revenue growth in the second half. The company is upping the EBIT margin outlook to 150 to 200 for the year against the previous outlook. As a result of the good progress expanding its EBIT margin, the company increased its operating margin guidance for the full year 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NBHGY:US $8.96 USD -0.09

NBHGY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
DENTSPLY International Inc $46.60 USD -0.105
Osstem Implant Co Ltd 38,200 KRW +200.00
Straumann Holding AG SFr.215.70 CHF -5.10
Zimmer Holdings Inc $103.99 USD -0.26
View Industry Companies

Industry Analysis


Industry Average

Valuation NBHGY Industry Range
Price/Earnings 32.7x
Price/Sales 2.9x
Price/Book 4.7x
Price/Cash Flow 32.9x
TEV/Sales 2.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOBEL BIOCARE HOLD-UNSP ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at